5 assets in Thyroid Gland Squamous Cell Carcinoma

Therapeutic assets addressing Thyroid Gland Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Thyroid Gland Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Thyroid Gland Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Thyroid Gland Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Thyroid Gland Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Thyroid Gland Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)